Home > Blog

Blog / 19 Nov 2026

Cell-free DNA and Cancer Detection: Key Study Findings

Context:

Recently, A pan-Indian study published in the Proceedings of the National Academy of Sciences (PNAS) found that higher levels of circulating DNA fragments in blood are associated with stronger cancer signals and improved detection sensitivity. The study highlights the potential of blood-based tests for early and less invasive cancer detection.

What is Cell-free DNA (cfDNA)?

Cell-free DNA (cfDNA) refers to small DNA fragments released into the bloodstream when cells die. A fraction of this DNA originates specifically from cancer cells and is known as circulating tumour DNA (ctDNA). Liquid biopsy is a minimally invasive diagnostic technique that examines blood or other body fluids to identify cancer-related biomarkers. Importantly, all ctDNA is cfDNA, but all cfDNA is not ctDNA.

Key Findings of the Study:

      • The study involved 1,480 participants across 43 hospitals in India and covered 14 cancer types. Researchers found that higher cfDNA levels were associated with stronger cancer signals and improved detection sensitivity, even among patients at the same cancer stage.
      • Earlier, scientists expected that DNA released by immune cells would dilute tumour-related DNA signals. However, the study found that DNA released by tumour cells and immune cells increased together, reinforcing cancer-associated signals.
      • Reported detection sensitivity increased from 55% to 85% for Stage I and 59% to 86% for Stage II cancer across lower and higher cfDNA groups.

About CancerSpot:

Developed by Bengaluru-based Strand Life Sciences, CancerSpot is a multi-cancer detection blood test. It analyses a single blood sample through DNA sequencing and Artificial Intelligence (AI) to identify cancer-associated DNA methylation patterns. The reported performance was 72% detection sensitivity with a 1.4% false-positive rate in an independent validation cohort.

What is DNA Methylation?

DNA methylation is an epigenetic process involving the addition of methyl groups to DNA. It regulates gene expression without changing the underlying DNA sequence. Abnormal methylation patterns can act as biomarkers for identifying cancer.

Significance for India:

The development could promote early cancer detection through less invasive screening, strengthen precision medicine and support indigenous biotechnology innovation. It may also improve understanding of tumour-immune interactions and complement existing cancer-screening programmes.

Conclusion:

The study highlights the potential of combining genomics, AI and biotechnology to transform cancer detection in India. However, multi-cancer blood tests should complement rather than replace established screening and diagnostic methods. Evidence-based adoption, affordability and equitable accessibility are essential for improving cancer care.

Aliganj Gomti Nagar Prayagraj